Monthly Archives: July 2014

Kineta, Children’s join in pediatric clinical-trial effort

Seattle biotechnology company Kineta and Seattle Children’s Research Institute are joining in an effort to improve development and testing of therapies for pediatric autoimmune diseases. Their collaboration, called Alliance for Children’s Therapeutics, will be funded both by philanthropic gifts to the research institute and equity investments in Kineta. Its initial aim is to raise $1.5 […]

Seattle Children’s Research Institute and Kineta Launch the Alliance for Children’s Therapeutics

Seattle Children’s Research Institute and biotechnology company Kineta, Inc. today launched the Alliance for Children’s Therapeutics (ACT), a first-of-its-kind pediatric research and funding collaboration designed to speed development of new medications for children and teens with lupus nephritis and other autoimmune diseases like multiple sclerosis, Type 1 diabetes and rheumatoid arthritis. “Funding for pediatric research lags disproportionately behind research funding […]

Kineta, Inc. and RLB Holdings Announce New Joint Venture to Address High-Need Therapeutics Including Autoimmune Diseases

Kineta, Inc., a biotechnology company focused on the development of immune-modulating drugs for critical diseases, and RLB Holdings, an investment fund founded by Ray and Lydia Bartoszek, have formed a joint venture, Kineta RLB, LLC, which will commercialize promising, high-value compounds in selective disease areas with unmet medical needs. “The vision of Kineta RLB is […]